Human IgG2 Variants of Chimeric Anti-CD3 Are Nonmitogenic to T Cells

Journal of Immunology

Volumn 159, Issue 7, 1997, Pages 3613-3621

  Cole, Michael S ^a   Anasetti, Claudio ^b   Tso, J Yun ^a  

^a PROTEIN DESIGN LABS INC   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CYTOKINE; FC RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOLOGICAL ADJUVANT; MITOGENIC AGENT; OKT 3;

ANIMAL; ANTIBODY AFFINITY; ARTICLE; DRUG EFFECT; GENETICS; HUMAN; IMMUNOGLOBULIN CONSTANT REGION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; PHYSIOLOGY; SITE DIRECTED MUTAGENESIS; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY AFFINITY; ANTIGENS, CD3; CYTOKINES; HUMANS; IMMUNOGLOBULIN CONSTANT REGIONS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN ISOTYPES; LYMPHOCYTE ACTIVATION; MICE; MITOGENS; MUROMONAB-CD3; MUTAGENESIS, SITE-DIRECTED; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 0031252326     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Abramowicz, D., L. Schandene, M Goldman, A. Crusiaux, P. Vereerstraeten, L. DePauw, J. Wybran, P. Kinnaert, E. Dupont, and C. Toussaint. 1989. Release of tumor necrosis factor-alpha and interferon-gamma in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 47: 606.
2. 2 fragments are immunosuppressive in vivo without evoking the strong humoral response or morbidity associated with whole mAb. Transplantation 49:1117.
3. Alegre, M.-L., J. Y. Tso, H. A. Sattar, J. Smith, M. S. Cole, and J. A. Bluestone. 1995. An anti-murine CD3 monoclonal antibody with a low affinity for Fcγ receptor suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J. Immunol. 155:1544.
4. Anasetti, C., P. Martin, R. Storb, F. R. Applebaum, P. G. Beatty, J. Davis, K. Doney. H. F. Hill, P. Stewart, K. M. Sullivan, R. P. Witherspoon, E. D. Thomas, and J. A. Hanson. 1992. Treatment of acute graft-versus-host disease with a non-mitogenic anti-CD3 monoclonal antibody. Transplantation 54:844.
5. Parlevliet, K. J., I. J. ten Berge, S. L. Yong, J. Surachno, J. M. Wilmink, and P. T. Schellekens. 1994. In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants. J. Clin. Invest. 93:2519.
6. Kim, J.-K., M.-F. Tsen, V. Ghertie, and E. S. Ward. 1994. Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis. Eur. J. Immunol. 24:542.
7. Ravetch, J. V., and J.-P. Kinet. 1991. Fc receptors. Anna. Rev. Immunol. 9:457.
8. Parren, P. W. H. I., P. A. M. Marmerdam, L. C. M. Boeije, P. J. A. Capel, J. G. J. van de Winkel, and L. A. Aarden. 1992. Characterization of IgG FcR-mediated proliferation of a human T cells induced by mouse and human anti-CD3 monoclonal antibodies. J. Immunol. 148:695.
9. Parren, P. W. H. I., P. A. M. Warmerdam, L. C. M. Boeije, J. Arts, N. A. C. Westerdaal, A. Vlug, P. J. A. Capel, L. A. Aarden, and J. G. J. Van de Winkel. 1992. On the interaction of IgG subclasses with the low affinity FcγRIIa (CD32) on human monocytes, neutrophils, and platelets. J. Clin. Invest. 90:1537.
10. Bolt, S., E. Routlege, I. Llyod, L. Chatenoud, H. Pope, S. D. Gorman, M. Clark, and H. Waldmann. 1993. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur. J. Immunol. 23:403.
11. Parren, P. W. H. I., M. E. J. Geerts, L. C. M. Boeije, and L. A. Aarden. 1991. Induction of T-cell proliferation by recombinant mouse and chimeric mouse/ human anti-CD3 monoclonal antibodies. Res. Immunol. 142:793.
12. Alegre, M.-L., L. J. Peterson, D. Xu, H. A. Sattar, D. R. Jeyarajah, K. Kowalkowski, J. R. Thistlethwaite, R. A. Zivin, L. Jolliffe, and J. A. Bluestone. 1994. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 57:1537.
13. Alegre, M.-L., A Collins, V. L. Pulito, R. L. Brosius, W. C. Olson, R. A. Zivin, R. Knowles, J. R. Thistlethwaite, L. K. Jolliffe, and J. A. Bluestone. 1992. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J. Immunol. 148:3461.
14. Willems, F., F. Andris, D. Xu, D. Abramowicz, M. Wissing, M. Goldman, and O. Leo. 1995. The induction of human T cell unresponsiveness by soluble anti-CD3 mAb requires T cell activation. Int. Immunol. 7:1593.
15. Lund, J., G. Winter, P. T. Jones, J. D. Pound, T. Tanaka, M. R. Walker, P. J. Artymuk, D. R. Burton, R. Jefferis, and J. M. Woof. 1991. Human FcγRI and FcγRII interact with distinct but overlapping sites on Human IgG. J. Immunol. 147:2657.
16. Routledge, E. G., M. E. Falconer, H. Pope, I. S. Lloyd, and H. Waldmann. 1995. The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. Transplantation 60:647.
17. Co, M. S., N. M. Avdalovic, P. C. Caron, M. V. Avdalovic, D. A. Scheinberg, and C. Queen. 1992. Chimeric and humanized antibodies with specificity for the CD33 antigen. J. Immunol. 148:1149.
18. Woodle, E. S., J. R. Thistlethwaite, L. K. Jolloffe, R. A. Zivin, A. Collins, J. R. Adair, M. Bodmer, D. Athwal, M. L. Alegre, and J. A. Bluestone. 1992. Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression. J. Immunol. 148:2756.
19. Ashfield, R., P. Enriquez-Harris, and N. J. Proudfoot 1991. Transcriptional termination between the closely linked human complement genes C2 and factor B: common termination factor for C2 and c-myc? EMBO J. 10:4197.
20. Boshart, M., F. Weber, G. Jahn, K. Dorsch-Hasler, B. Fleckenstein, and W. Schaffner. 1985. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 41:521.
21. Kostelny, S. K., M. S. Cole, and J. Y. Tso. 1992. Formation of a bispecific antibody by the use of leucine zippers. J. Immunol. 148:1547.
22. 2 targeted to the human IL-2 receptor. J. Hematother. 4:389.
23. Warmerdam, P. A., J. G. van de Winkel, A. Vlug, N. A. Westerdaal, and P. J. Capel. 1991. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J. Immunol. 147:1338.
24. Fraker, P. J., and J. C. Speck. 1978. Protein and cell-membrane iodination with a sparing soluble choramide, 1,3,4,6-terachloro-3α,6α-diphenyl-glycouril. Biochem. Biophys. RfS. Commun. 80:849.
25. Scatchard, G. 1949. The attractions of small proteins for small molecules and ions. Ann. NY Acad. Sci. 51:660.
26. Berofsky, J. A., and I. J. Berkower. 1984. Immunogenicily and antigen structure. In Fundamental Immunology. W. E. Paul, ed. Raven Press, New York, p. 595.
27. Edelman, G. M., B. A. Cunningham, W. E. Gall, P. D. Gottlieb, U. Rutishauser, and M. J. Waxdal. 1969. The covalent structure of an entire gammaG immunoglobulin molecule. Proc. Natl. Acad. Sci. USA 63:78.
28. Adair, J. R., D. S. Athwal, M. W. Bodmer, S. M. Bright, A. M. Collins, V. L. Pulito, P. E. Rao, R. Reedman, A. L. Rothermel, and D. Xu. 1994. Humanization of the murine anti-human CD3 monoclonal antibody OKT3. Hum. Antibodies Hvbridomas 5:41.
29. Morelock, M. M., R. Rothlein, S. M. Bright, M. K. Robinson, E. T. Graham, J. P. Sabo, R. Owens, D. J. King, S. H. Norris, D. S. Scher, J. L. Wright, and J. R. Adair. 1994. Isotype choice for chimeric antibodies affects binding properties. J. Biol. Chem. 269:13048.
30. 2 fragments: retention of the immunosuppressive properties of whole antibody with marked reduction in T cell activation and lymphokine release. Transplantation 52:354.
31. Flamand, V., V. Donckier, D. Abramowicz, M. Goldman, P. Vandenabeele, J. Urbain, M. Moser, and O. Leo. 1994. In vivo immunosuppression induced by a weakly mitogenic antibody Io mouse CD3: evidence that induction of long-lasting in vivo unresponsiveness requires TCR signaling. Cell. Immunol. 157: 239.
32. Vossen, A. C., G. J. Tibbe, M. J. Kroos, J. G. van de Winkel, R. Benner, and H. F. Savelkoul. 1995. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects. Eur. J. Immunol. 25:1492.
33. 2 in antigen receptor transgenic murine T cells activated by specific peptide. J. Immunol. 157:3420.
34. Smith, J. A., J. Y. Tso, M. R. Clark, M. S. Cole, and J. A. Bluestone. 1997. Non-mitogenic anti-CD3 Mabs deliver a partial TCR signal and influence clonal anergy. J. Exp. Med. 185:1413.
35. Routledge, E., I. Lloyd, S. D. Gorman, M. Clark, and H. Waldmann. 1991. A humanized monovalent CD3 antibody which can activate homologous complement. Eur. J. Immunol. 21:2717.
36. Bruggemann, M., G. T. Williams, C. I. Bindon, M. R. Clark, M. R. Walker, R. Jefferis, H. Waldmann, and M. S. Neuberger. 1987. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 166:1351.
37. Steplewski, Z., L. K. Sun, C. W. Shearman, J. Ghrayeb, P. E. Daddona, and H. Koprowski. 1988. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc. Natl. Acad. Sci. USA 85:4852.